Last reviewed · How we verify
Reference formulation of HRS-1893 tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Reference formulation of HRS-1893 tablet (Reference formulation of HRS-1893 tablet) — Shandong Suncadia Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Reference formulation of HRS-1893 tablet TARGET | Reference formulation of HRS-1893 tablet | Shandong Suncadia Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Reference formulation of HRS-1893 tablet CI watch — RSS
- Reference formulation of HRS-1893 tablet CI watch — Atom
- Reference formulation of HRS-1893 tablet CI watch — JSON
- Reference formulation of HRS-1893 tablet alone — RSS
Cite this brief
Drug Landscape (2026). Reference formulation of HRS-1893 tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/reference-formulation-of-hrs-1893-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab